4 ms·
The headline is terrible given the thesis of the short article. The Economist's analysis creates a model that shows Pharma companies making "excess profits" (g
by tptacek 1y ago
The headline is terrible given the thesis of the short article.
The Economist's analysis creates a model that shows Pharma companies making "excess profits" (greater than 10% return on capital) second only to technology companies. In that sense, by the Economist's terms, they are in fact gouging.
But that's not really the point the Economist wants to make; rather, regardless of whatever profits Pharma is raking in, they're in fact a small component of overall health care spending. You could zero out Pharma profits (this is my point and not theirs) and not materially change US health spending.
In all these discussions about American health care, my first take is that everybody should go download the CMS National Health Expenditures, and make a beeline for "Expenditures by Type of Expenditure and Program" (it's just an Excel spreadsheet). It's an extremely intuitive breakdown of where all US health care spending goes, and who's paying for it, all on one sheet.
There are a lot of narratives about health care spending that do not survive first contact with that spreadsheet.
- kspacewalk2 1y agoAre you specifically referring to `Table 19 National Health Expenditures by Type of Expenditure and Program.xlsx` in the ZIP archive which can be downloaded at https://www.cms.gov/files/zip/nhe-tables.zip https://www.cms.gov/files/zip/nhe-tables.zip ?
- tptacek 1y agoYeah the one I have hotlinked in Google Sheets is a "Table 19" but I didn't want to presume it's Table 19 every year.
- dboreham 1y agoDrug costs are contentious because they're easily visible and often no covered by insurance. The other costs are obfuscated in complex billing and hidden under principle/agent veils. E.g. my son has a peanut allergy and so we need to buy EpiPens. They were hundreds of dollars, and the vendor played MBA-nonsense games like requiring two to be purchased at a time. Meanwhile I was able to drive to Canada and buy the exact same thing (and as many or as few as I needed) for tens of dollars.
- tptacek 1y agoWe know where all the health spending in the system ends up, and while Pharma pricing is quite high and those companies are quite profitable, most of our health spending doesn't go to either Pharma or insurers.
- megaman821 1y agoThat is annoying, but not a huge cost driver. If you son ended up in the ER it would cost multiple lifetimes of epipens (even at an inflated price).
- pixl97 1y agoI mean, this is a bit of circular logic isn't it... "Medicine being expensive doesn't impact care being expensive" Which is almost exactly the opposite. If people could get cheap general doctor visits and be able to afford their medicines then this would reduce the number of emergency visits allowing less beds/doctors/hospitals.
- cyberax 1y agoSimilar story. I suffer from dry eyes, and I like perfluorohexyloctane eye drops. They require a prescription and cost $800 here in the US. I am now ordering them from an Irish pharmacy. They are over the counter there, and cost $20. They are literally exactly the same, you can tell by the lot numbers on the bottles.
- botro 1y agoI've suffered from dry eyes for many years and have tried all the over the counter options available in the US with no success, especially for overnight dryness. Could you please share a hint for the Irish pharmacy delivering to the US?
- cyberax 1y agoSearch for "EvoTears" or "NovoTears", it's the European brand for it. I've been using this pharmacy: https://www.opticalrooms.ie/product/evotears/ https://www.opticalrooms.ie/product/evotears/ There are others that apparently can ship to the US.
- abeppu 1y agoI don't think the spending story alone is helpful because it doesn't acknowledge where there's room for actual improvement. Of the $1.5T spent on "Hospital Care", if almost all of it went to medical staff, facilities, equipment etc, and if good data suggested that people aren't in hospital unnecessarily, maybe that number isn't a problem. But if private hospitals have very fat margins, and some significant share of patients could be served just as well through less expensive clinical services, maybe that's too much. In the context of the cost of medication, the $449B on "prescription drugs" doesn't break out what goes to drug makers vs PBMs or anyone else. We can easily imagine a world without PBMs that still delivers drugs to patients, but someone has to actually make the drugs. We can also ask, are people on medications they don't actually need? Are we sometimes _causing_ later health issues when medicating (e.g. fueling a giant opioid crisis)? None of this is apparent in the top-line spending figures.
- tptacek 1y agoWhoah, that smuggles in an enormous assumption: that a dollar directed to a medical professional is automatically well spent. In reality, medical professionals in the US make drastically more money than they do in Europe and deliver way more procedures (they're often working on "RVU" scales that incentivize delivery of more procedures). This is something that makes health care economics really difficult to discuss: everybody trusts their doctor and factors them out of the equation; the problem is every penny that doesn't go to their doctors and specialists. But that's not a valid analysis and your doctor and their support system is (after elder care) at the heart of US health spending.
- abeppu 1y agoI did _not_ make that assumption. I specifically called out the possibility that some hospital care may not be necessary. Regarding hospital care, the two sentences describing hypotheticals where spending is or is not improvable specifically included clauses: > and if good data suggested that people aren't in hospital unnecessarily > if ... some significant share of patients could be served just as well through less expensive clinical services, maybe that's too much
- dang 1y agoThanks - I've adapted your phrase for the title above. If anyone can suggest a better (i.e. more accurate and neutral), we can change it again.
- PaulHoule 1y agoMy understanding also is that pharma is a case where you can often show you spend $X on a medicine and it gives $10X or more in savings. For instance inhaled steroids for asthma can cost an eye-popping $300 a month but some people with asthma get hospitalized once a year at a cost upwards of $8000 so the inhaler is really a bargain.
- firstplacelast 1y agoThat's like saying smoke detectors should cost thousands of dollars bc they can save a 500K+ building. That's a poor way to look at value in these situations. It's cheap and easy to make, so it should be cheap to the consumer if there weren't all sorts of red-tape and opaque pricing schemes used as an excuse to prop of extortion.
- tptacek 1y agoWhy is that a poor way of looking at the situation? The reason smoke detectors don't cost thousands of dollars is that there are lots of different smoke detectors competing the price down.
- thephyber 1y agoWhile that is a great point and should be done, one of the most dysfunctional part of the healthcare system is that the end user / patient doesn’t know how much they will pay if they opt to get a thing done. The obscurity of the price _before_ agreeing to get it done is not reflected at all in data which is 100% hindsight. My old boss described it this way: without price transparency medical care isn’t a market, it’s a racket. And all of the managers in health care are working to remove price transparency to increase their margins.
- _DeadFred_ 1y agoAs someone who wasted the good years of their life trying to improve the medical system in the USA, there is no piecemeal way to fix it. We were able to save a ton of money but it didn't matter, the saving just vanished into the void that is US medical care and costs went up.